Press Releases

Press Releases

  1. Centers Commence Enrollment in KNOCOUT PE Study to Measure the Impact of Shorter, Even Safer EKOS® Therapy Protocols for Pulmonary Embolism

  2. Institutional Decision to Adopt Y90 TARE with TheraSphere® as first-line treatment for HCC

  3. New consensus guidelines provide specific recommendations for use of Voraxaze® in patients with delayed methotrexate clearance

  4. Directorate change – Chief Financial Officer

  5. BTG plc: Interim Results 2017

  6. BTG plc: update on legal ruling

  7. BTG plc: Varithena® receives finalised category I CPT codes

  8. First patient treated with microscopic beads pre-loaded with a targeted cancer drug and visible on CT scans

  9. BTG plc: close period update

  10. BTG plc acquires Roxwood Medical

  11. BTG and Mirada Medical Sign Three-Year Software Development Agreement

  12. BTG plc: legal ruling

  13. Vistogard® and Voraxaze® Added to Revised Guidelines for Stocking of Antidotes in US Hospitals

  14. BTG and SIO expand Immuno-Oncology / Interventional Oncology grant programme

  15. BTG plc: Annual General Meeting

  16. ACCESS PTS Study Demonstrates Efficacy of EKOS® Therapy for Post-Thrombotic Syndrome

  17. New Study Shows Patients Treated With CroFab® Have Improved Recovery From Copperhead Envenomation

  18. New study shows IO Loop™ improves patient follow-up, engagement and satisfaction following treatment with TheraSphere®

  19. SIO announces first grants in Interventional Oncology / Immuno-Oncology research programme

  20. OPTALYSE PE Study Demonstrates Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism

  21. BTG and HealthLoop collaborate on IO Loop™, an exclusive service to connect patients and interventional oncologists throughout treatment

  22. BTG plc: Final Results 2017

  23. First European Patients Treated With DC Bead LUMI™ Radiopaque Drug-Eluting Beads

  24. BTG plc: close period update

  25. SnakeBite911™ Expands Free Snake Education and Snakebite Safety App to Android Devices

  26. BTG announces CE Mark Certification for DC Bead LUMI™, the First commercially available Radiopaque Drug-Eluting Bead

  27. BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

  28. BTG and Society of Interventional Oncology to explore role of minimally invasive therapies in immuno-oncology

  29. New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians

  30. First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® system